Dr Nota Zarmpi
About
Biography
Dr. Nota Zarmpi is a Lecturer in Pharmaceutical Sciences at the University of Surrey. She earned her B.A.Sc. in Pharmaceutical Sciences from the National and Kapodistrian University of Athens, Greece, in 2015, followed by a Ph.D. in Pharmacy and Pharmacology from the University of Bath in 2019. Her doctoral research focused on assessing the impact of excipient variability on the performance of oral drug products.
In 2019, Dr. Zarmpi joined the Skin Research Group led by Professors Richard Guy and Begoña Delgado-Charro at Bath, where her postdoctoral research explored the applications of non-invasive techniques—specifically Confocal Raman Spectroscopy—in topical and transdermal drug delivery. A groundbreaking achievement of her work was demonstrating that vibrational spectroscopies can successfully differentiate bioequivalent medicinal products from non-equivalent ones non-invasively and in real-world scenarios. This research was prominently featured in the 2023 GDUFA Science and Research Report by the Office of Generic Drugs at the FDA..
ResearchResearch interests
Dr. Nota Zarmpi's research focuses on pharmaceutics, specifically on modifying a medicine’s properties to optimize its interaction with the body, enhancing both safety and efficacy. Since 2019, she has been studying drug permeation across the skin following the application of dermatological products. Her work aims to characterize formulations, assess skin bioavailability (BA)—the rate and extent of drug delivery to the site of action—and evaluate bioequivalence (BE) between innovator and generic products.
Her research is driven by the limitations of current methods used to assess skin bioavailability. Existing approaches are either restricted to a narrow range of active compounds or are invasive, technically complex, labor-intensive, costly, and often insensitive, particularly in the context of clinical trials. Therefore, Dr. Zarmpi's work seeks to develop validated, non-invasive approaches for determining drug bioavailability from complex medicines, including topical formulations. Such advancements will facilitate faster and more reliable approval processes for generic products.
Research interests
Dr. Nota Zarmpi's research focuses on pharmaceutics, specifically on modifying a medicine’s properties to optimize its interaction with the body, enhancing both safety and efficacy. Since 2019, she has been studying drug permeation across the skin following the application of dermatological products. Her work aims to characterize formulations, assess skin bioavailability (BA)—the rate and extent of drug delivery to the site of action—and evaluate bioequivalence (BE) between innovator and generic products.
Her research is driven by the limitations of current methods used to assess skin bioavailability. Existing approaches are either restricted to a narrow range of active compounds or are invasive, technically complex, labor-intensive, costly, and often insensitive, particularly in the context of clinical trials. Therefore, Dr. Zarmpi's work seeks to develop validated, non-invasive approaches for determining drug bioavailability from complex medicines, including topical formulations. Such advancements will facilitate faster and more reliable approval processes for generic products.